MedTrace Logo

Effect of the Atazanavir (ATV) 150L Mutation on Subsequent Treatment Response in HIV Infected Subjects

NCT00096746 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2011-04-13

No results posted yet for this study

Summary

This study will compare the response of subjects who failed a first-line ATV-containing regimen and who have the 150L-containing virus to subsequent protease inhibitor (PI)-containing therapy with that of a cohort who has failed a first-line reverse transcriptase inhibitor (NNRTI), and is subsequently receiving PI-containing therapy.

Conditions

  • HIV Infection

Interventions

DRUG

LPV/RTV + 2NRTIs

Tablets, Oral, Variable, Twice daily, 48 weeks.

DRUG

LPV/RTV + 2NRTIs

Tablets, Oral, Variable, Twice daily, 48 weeks.

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-11-30
Primary Completion
2006-09-30
Completion
2006-09-30

Countries

  • United States
  • Argentina
  • Brazil
  • Guatemala
  • Mexico
  • Peru
  • South Africa

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00096746 on ClinicalTrials.gov